A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626).

@article{Dahlberg2011ARP,
  title={A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626).},
  author={Suzanne E Dahlberg and Sakkaraiappan Ramalingam and Chandra Prakash Belani and Joan Hoff Schiller},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={TPS218}
}
TPS218 Background: In ECOG 4599, bevacizumab was continued as maintenance therapy following 6 cycles of PCB. This study led to the approval of PCB followed by B for first-line treatment of advanced non-squamous NSCLC by the FDA. Switch maintenance therapy with Pm has recently demonstrated survival benefit for non-squamous NSCLC. Therefore ECOG 5508 will compare the efficacy of continuation of B vs. switch to Pm or the BPm combination after 4 cycles of PCB. METHODS The primary objective is to… CONTINUE READING
11 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…